bao gong teng A: tropane alkaloid from Erycibe obtusifolia Benth; causes strong myosis in rabbits; MF is C9-H15-O3-N; RN given refers to (exo,exo)-(-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Erycibe | genus | [no description available] | Convolvulaceae | The morning glory family of flowering plants, of the order Solanales, which includes about 50 genera and at least 1,400 species. Leaves are alternate and flowers are funnel-shaped. Most are twining and erect herbs, with a few woody vines, trees, and shrubs.[MeSH] |
| Erycibe obtusifolia | species | [no description available] | Convolvulaceae | The morning glory family of flowering plants, of the order Solanales, which includes about 50 genera and at least 1,400 species. Leaves are alternate and flowers are funnel-shaped. Most are twining and erect herbs, with a few woody vines, trees, and shrubs.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 156282 |
| MeSH ID | M0090204 |
| Synonym |
|---|
| erycibe alkaloid ii |
| bao gong teng a |
| 8-azabicyclo(3.2.1)octane-3,6-diol, 6-acetate, (exo,exo)-(-)- |
| 2-hydroxy-8-azabicyclo[3.2.1]octan-6-yl acetate |
| DTXSID30995718 |
| GLXC-18494 |
| [(1r,2s,5r,6s)-2-hydroxy-8-azabicyclo[3.2.1]octan-6-yl] acetate |
| (1r,2s,5r,6s)-2-hydroxy-8-azabicyclo[3.2.1]octan-6-yl acetate |
| bgt-a |
| AKOS040734424 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Finally, in a subacute toxicity study of EWA, alterations observed with high dosage suggest that the liver and kidney could be the target organs of toxicity." | ( Toxicology and the chemical foundation of plants of Erycibe. Chen, Z; Liao, L; Wang, L; Wang, Z; Zhang, Z, 2014) | 0.4 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.82) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||